Contrave Bound For Korea As Orexigen Links With Local Firm
This article was originally published in PharmAsia News
Executive Summary
After settling a long dispute with its marketing partner for the US market, Orexigen Therapeutics has inked an agreement with Kwang Dong Pharm to distribute its obesity drug in South Korea, where demand is growing amid an increasing number of hypertension, hyperlipidemia and diabetes patients.